These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 15728894

  • 1. Pulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.
    Gracia M, Martínez-Marín C, Huelves L, Giménez MJ, Aguilar L, Carcas A, Ponte C, Soriano F.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):996-1001. PubMed ID: 15728894
    [Abstract] [Full Text] [Related]

  • 2. Correlation between in vitro and in vivo activity of amoxicillin against Streptococcus pneumoniae in a murine pneumonia model.
    Moine P, Mazoit JX, Bédos JP, Vallée E, Azoulay-Dupuis E.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):310-5. PubMed ID: 8996211
    [Abstract] [Full Text] [Related]

  • 3. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML, García Y, Valero E, Amores R, Fuentes F.
    Rev Esp Quimioter; 2000 Sep; 13(3):306-13. PubMed ID: 11086282
    [Abstract] [Full Text] [Related]

  • 4. Beta-lactam activity against penicillin-resistant Streptococcus pneumoniae strains exhibiting higher amoxicillin versus penicillin minimum inhibitory concentration values: an in vitro pharmacodynamic simulation.
    Sevillano D, Aguilar L, Alou L, Giménez MJ, González N, Echeverría O, Torrico M, Valdes L, Coronel P, Prieto J.
    Chemotherapy; 2008 Sep; 54(2):84-90. PubMed ID: 18303256
    [Abstract] [Full Text] [Related]

  • 5. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?
    Falcó V, Almirante B, Jordano Q, Calonge L, del Valle O, Pigrau C, Planes AM, Gavaldà J, Pahissa A.
    J Antimicrob Chemother; 2004 Aug; 54(2):481-8. PubMed ID: 15215226
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S, Erdem H, Pahsa A.
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [Abstract] [Full Text] [Related]

  • 7. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
    Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J.
    J Antimicrob Chemother; 2004 Dec; 54(6):1148-51. PubMed ID: 15489246
    [Abstract] [Full Text] [Related]

  • 8. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
    Amores R, Alou L, Giménez MJ, Sevillano D, Gómez-Lus ML, Aguilar L, Prieto J.
    Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.
    Sun HK, Lee SY, Banevicius MA, Du X, Maglio D, Nicolau DP.
    J Antimicrob Chemother; 2005 Sep; 56(3):559-65. PubMed ID: 16024590
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, Twynholm M, Dal-Ré R, 620 Clinical Study Group.
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [Abstract] [Full Text] [Related]

  • 11. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):29-34. PubMed ID: 9869561
    [Abstract] [Full Text] [Related]

  • 12. Streptococcus pneumoniae pneumonia in mice: optimal amoxicillin dosing predicted from a pharmacokinetic-pharmacodynamic model.
    Moine P, Mazoit JX.
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1086-92. PubMed ID: 10565828
    [Abstract] [Full Text] [Related]

  • 13. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae.
    Cha R, Rybak MJ.
    J Antimicrob Chemother; 2004 Dec; 54(6):1067-71. PubMed ID: 15486084
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
    Odenholt I, Cars O, Löwdin E.
    J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C, Suárez L, Rubio-Calvo C, Gómez-Lus R, Gimeno M, Coronel P, Durán E, Becerril R, Oca M, Castillo FJ.
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [Abstract] [Full Text] [Related]

  • 16. Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by beta-lactam-susceptible and highly resistant pneumococci.
    Rodríguez-Cerrato V, Del Prado G, Huelves L, Naves P, Ruiz V, García E, Ponte C, Soriano F.
    Int J Antimicrob Agents; 2010 Jun; 35(6):544-9. PubMed ID: 20303716
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F, Fernández-Cuenca F, Pachón-Ibáñez ME, Pascual A, Pichardo C, Martínez-Martínez L, Pachón J.
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [Abstract] [Full Text] [Related]

  • 18. Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy volunteers.
    Ponte C, Gracia M, Giménez MJ, Aguilar L, Maín CM, Carpintero Y, Huelves L, Carcas A, del Prado G, Soriano F.
    Clin Ther; 2005 Jul; 27(7):1043-9. PubMed ID: 16154483
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):35-40. PubMed ID: 9869562
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
    Zhanel GG, Derkatch S, Laing N, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.